PainReform Announces Development And Manufacturing Of New Formulations Providing Anti-Inflammatory And Extended Analgesic Effects
Portfolio Pulse from Benzinga Newsdesk
PainReform Ltd. (NASDAQ:PRFX) has announced the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These formulations incorporate both an analgesic and an anti-inflammatory agent, designed to enhance postoperative recovery and reduce opioid reliance.
August 12, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PainReform Ltd. has developed new patented formulations of PRF-110, which combine analgesic and anti-inflammatory agents to enhance postoperative recovery and reduce opioid reliance.
The development of new patented formulations that enhance postoperative recovery and reduce opioid reliance is a significant advancement for PainReform Ltd. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100